AtriCure Inc (ATRC)vsBecton Dickinson and Company (BDX)
ATRC
AtriCure Inc
$29.53
-0.27%
HEALTHCARE · Cap: $1.47B
BDX
Becton Dickinson and Company
$158.27
+1.51%
HEALTHCARE · Cap: $56.49B
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 4002% more annual revenue ($21.92B vs $534.53M). BDX leads profitability with a 8.0% profit margin vs -2.1%. BDX appears more attractively valued with a PEG of 1.16. BDX earns a higher WallStSmart Score of 61/100 (C+).
ATRC
Hold37
out of 100
Grade: F
BDX
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ATRC.
Margin of Safety
+36.9%
Fair Value
$286.42
Current Price
$158.27
$128.15 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Reasonable price relative to book value
Earnings expanding 28.6% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 1.8%
Expensive relative to growth rate
Moderate valuation
1.6% revenue growth
ROE of 7.0% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ATRC
The strongest argument for ATRC centers on Price/Book. Revenue growth of 13.1% demonstrates continued momentum.
Bull Case : BDX
The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bear Case : ATRC
The primary concerns for ATRC are EPS Growth, Market Cap, Operating Margin.
Bear Case : BDX
The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.
Key Dynamics to Monitor
ATRC profiles as a turnaround stock while BDX is a value play — different risk/reward profiles.
ATRC carries more volatility with a beta of 1.44 — expect wider price swings.
ATRC is growing revenue faster at 13.1% — sustainability is the question.
BDX generates stronger free cash flow (549M), providing more financial flexibility.
Bottom Line
BDX scores higher overall (61/100 vs 37/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AtriCure Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. The company is headquartered in Mason, Ohio.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?